During the corresponding time, Radnostix Inc saw a revenue deteriorated by -14.95 % year on year, sequentially revenue grew by 24.21 %. While revenue at the Radnostix Inc's corporate clients
Radnostix Inc's Comment on Sales, Marketing and Customers
The company operates in the theranostics market by producing and distributing isotopically pure radiopharmaceuticals, active pharmaceutical ingredients (APIs), and radiochemicals for medical, industrial, and research applications. It offers an FDA-approved generic sodium iodide I-131 drug product as a domestic alternative to a foreign commercial manufacturer. The Cobalt Products segment supplies cobalt-60 products for radiation therapy, industrial and medical uses, and cobalt-60 source recycling, adhering to regulations in the US, EU, China, Australia, Brazil, and Argentina. The Calibration & Reference Products segment, marketed through the RadQual subsidiary, serves users of SPECT and PET imaging equipment, radiopharmacy and radiopharmaceutical CDMO laboratories, pre-clinical imaging, clinical trials, and calibration/testing of measuring equipment. Its product range includes sealed source calibration and reference products, flood sources, dose calibrator sources, phantoms, and specialty design items. Pre-clinical products are distributed via Phantech and the PhanQual joint venture with Phantech. Customers and markets referenced in filings include PhanQual, Phantech, and RadQual.
Radnostix Inc’s Comment on Sales, Marketing and Customers
The company operates in the theranostics market by producing and distributing isotopically pure radiopharmaceuticals, active pharmaceutical ingredients (APIs), and radiochemicals for medical, industrial, and research applications. It offers an FDA-approved generic sodium iodide I-131 drug product as a domestic alternative to a foreign commercial manufacturer. The Cobalt Products segment supplies cobalt-60 products for radiation therapy, industrial and medical uses, and cobalt-60 source recycling, adhering to regulations in the US, EU, China, Australia, Brazil, and Argentina. The Calibration & Reference Products segment, marketed through the RadQual subsidiary, serves users of SPECT and PET imaging equipment, radiopharmacy and radiopharmaceutical CDMO laboratories, pre-clinical imaging, clinical trials, and calibration/testing of measuring equipment. Its product range includes sealed source calibration and reference products, flood sources, dose calibrator sources, phantoms, and specialty design items. Pre-clinical products are distributed via Phantech and the PhanQual joint venture with Phantech. Customers and markets referenced in filings include PhanQual, Phantech, and RadQual.
Sources:
Radnostix Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Radnostix Inc’s corporate clients.
For your research, we’ve provided 9 tables on Radnostix Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
92.63 %